2Morrow, Inc.
2Morrow, Inc. is a company.
Active
Updated: ·
About
2Morrow, Inc. is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at 2Morrow, Inc..
2Morrow, Inc. is a company.
2Morrow, Inc. is a company.
Key people at 2Morrow, Inc..
2Morrow, Inc. is a digital health company that develops evidence-based mobile programs for behavior change, focusing on wellness areas like smoking cessation, chronic pain management, and mental health support such as grief.[1][5][6] It serves large employers, states, health plans, and individuals by delivering smartphone-based therapeutics that combine behavioral science with technology, helping over half a million users through brief, bundled programs emphasizing valued action and coaching.[1][5] With around 17-32 employees and $1 million in annual revenue, 2Morrow stands out for its research rigor, including over 20 studies and a Phase III clinical trial, positioning it as a leader in digital therapeutics recognized among the top 20 innovative companies of 2025.[1][6]
The company solves accessibility barriers in behavioral health by offering scalable, clinically validated apps that promote lasting change without requiring in-person care, bundling programs for interconnected behaviors like tobacco use and stress.[5] Growth momentum includes NIH grants, peer-reviewed publications, and pandemic-driven demand that made 2020 its best year, with expansions into pain and grief programs.[6]
Founded in 2011 (with some sources noting 2012), 2Morrow was co-founded by Jo Masterson (CEO) and Brandon Masterson (COO/CTO, original founder)—a nurse and a medical device engineer—who pioneered mobile behavior change before "digital health" was mainstream.[1][3][6] Brandon, with prior experience in digital media, e-commerce, and medical devices, drove the vision of usability for users and sponsors, while Jo brought healthcare expertise; they co-founded as partners, blending personal and professional commitment.[3][6]
The idea emerged from recognizing smartphones' potential to democratize behavioral science for chronic issues like smoking, leading to early traction via evidence-building, including a Phase III trial for tobacco cessation involving 2,400 participants and 12+ publications.[1][6] Pivotal moments include securing NIH grants for pain programs and capitalizing on 2020's remote health surge with a grief program, solidifying its research-first DNA.[6]
2Morrow rides the digital therapeutics (DTx) wave, addressing chronic behavioral health gaps amid rising demand for remote, scalable solutions post-pandemic.[6] Timing aligns with mHealth growth, where employers and health plans seek cost-effective alternatives to traditional care for issues like tobacco (affecting millions) and pain, amplified by evidence mandates from payers.[1][5][6]
Market forces favor it: smartphone penetration enables anytime access, while regulatory progress in DTx (e.g., FDA interest) rewards clinical validation, giving 2Morrow an edge over less-studied competitors.[1][6] It influences the ecosystem by setting evidence standards—via trials and publications—pushing the industry toward outcomes-based models and bundled interventions, benefiting startups in wellness tech.[4][5]
2Morrow is poised for expansion in DTx, leveraging 2025 recognition and partnerships to scale beyond tobacco into pain, mental health, and bundled wellness suites amid payer adoption of evidence-based apps.[6] Trends like AI-enhanced personalization, global mHealth growth, and chronic disease burdens will shape its path, potentially via acquisitions or FDA-cleared status.
Its influence may evolve by inspiring values-focused design in digital health, amplifying impact as remote care normalizes—ultimately helping millions act on what matters, as its mission promises.[5][7]
Key people at 2Morrow, Inc..
